Abstract

Neoadjuvant endocrine therapy for breast cancer is a focus issue in recent years. The aro-matase inhibitors are important drugs among it. Newer generation aromatase inhibitors are superior to tamoxifen as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer and have a promising prospect in clinical practice. Still some treatment-related problems remain to be discussed and further researched. Key words: Breast neoplasms; Aromatase inhibitors; Neoadjuvant therapy

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call